Airway anti-inflammatory effect can be maintained after salmeterol/fluticasone combination inhaler therapy is stepped down from medium to low dose for mild to moderate persistent asthmatics

Airway anti-inflammatory effect can be maintained after salmeterol/fluticasone combination inhaler therapy is stepped down from medium to low dose for mild to moderate persistent asthmatics - Anti-inflammatory effect after SFC step down

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019965

Enrollment

Registered

2015-11-28

Start date

2013-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

To continue 1 year treatment with SFC250 or To receive step down treatment with SFC100

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The asthmatics treated for at least 6 months with SFC 250 Diskus 2 puffs daily therapy, in whom the disease was well-controlled or totally controlled,i.e., an ACT score of 20-25 points, were eligible

Exclusion criteria

Exclusion criteria: Current smokers, those who had a smoking history (smoking index > 400) and patients with suspected COPD were excluded

Design outcomes

Primary

Measure	Time frame
The change of FeNO value after 1 year treatment	—

Countries

Japan

Contacts

Public ContactMasayuki Hojo

National Center for Global Health and Medicine Division of Respiratory Medicine

mhojo@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026